Tenvie Therapeutics
South San Francisco
About Tenvie Therapeutics
Tenvie Therapeutics is a biotechnology company founded to improve patients' lives with neurological, cardiometabolic, and ophthalmic diseases. The company is focused on developing small molecules targeting brain inflammation, metabolic dysfunction, and lysosomal issues, with a robust pipeline inherited from Denali Therapeutics. Tenvie is progressing a range of therapeutics aimed at addressing neurological, cardiometabolic, and ophthalmic conditions. Its collection of fully owned, highly brain-penetrant, and precisely designed peripherally restricted small molecules targets three main factors of disease: alleviating inflammation, correcting metabolic dysfunction, and rejuvenating lysosomal function.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Total funding: $200.0M
- Funding stage: Early Stage Venture
- Last round: Series A (Jan 2025)
- Website: tenvie.com
- Phone: [email protected]
Industries & Categories
Biotechnology, Medical, Neuroscience, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/tenvie-therapeutics-35782 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.